Therapeutic compositions and methods
PAD4 inhibitory compositions and methods for their use in treatment of cancer and autoimmune disease are provided according to embodiments of the present invention.
1. A composition comprising a substance having the structural formula selected from the group consisting of:
where n is 1 or 2; X is halogen; each Y is independently H, halogen, an O-linked aliphatic substituent or an N-linked aliphatic substituent; R 1 is an aromatic substituent; and R2 is an aliphatic or aromatic substituent;
a salt, stereoisomer, hydrate, amide or ester thereof; and a mixture of any two or more thereof.
2. The composition of claim 1 , wherein the substance has the structural formula selected from the group consisting of: YW3-56Br, YW3-56A-F, YW3-56A-Br,
a salt, stereoisomer, hydrate, amide or ester thereof; and a mixture of any two or more thereof.
3. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
4. The composition of claim 1 , wherein the substance has the structural formula:
where n is 1 or 2; X is halogen; Y 1 and Y 2 are each independently H, halogen, an O-linked aliphatic substituent or an N-linked aliphatic substituent; R 1 is an aromatic substituent; and R 2 is an aliphatic or aromatic substituent.
5. The composition of claim 4 , wherein n is 1, Y 1 and Y 2 are both H and X is F or Cl.
6. The composition of claim 5 , wherein the substance has a structural formula selected from the group consisting of:
YW3-56, YW3-56F, YW3-56Br, YW3-56A, YW3-56A-F, YW3-56A-Br; a salt, stereoisomer, hydrate, amide or ester thereof; and a mixture of any two or more thereof.
7. A commercial package comprising:
one or more substances according to claim 1 ; a salt, stereoisomer, hydrate, amide or ester thereof; and a mixture of any two or more thereof.
8. The commercial package of claim 7 , further comprising an ancillary component selected from the group consisting of: a pharmaceutically acceptable carrier, a buffer, a diluent and a reconstituting agent.